EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 200 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Grandparents of children with cancer: “I would never want to go... September 1, 2020 Aromatase inhibitors cut breast cancer recurrence in younger patients February 11, 2022 New on NCI Websites for June 2018 June 25, 2018 These Triplets Were Tired Of Being Mistaken For Each Other. Their... June 14, 2019 Load more HOT NEWS Pembrolizumab Demonstrates Robust and Durable Antitumour Activity in Patients with Previously... Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations ¿El azúcar provoca cáncer? New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where...
